It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

The experimental drug puts semaglutide, the ingredient in Ozempic and the weight-loss drug Wegovy, together with a medicine called cagrilintide to make the combination Novo Nordisk calls CagriSema.

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.

Achieve superior weight reduction with the synergistic effects of Cagrilintide and Semaglutide”. The FDA has not approved any treatment with cagrilintide, with the agency previously saying ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...